“How Ono Pharmaceutical can maximize the gap in competitive edge”

This is a follow-up post to “For MSD to fill the gap in competitive edge”

In terms of the gap n competitive edge between Ono Pharmaceutical and MSD in the oncology field’s number of medical representatives (MRs), Ono Pharmaceutical clearly has a superiority, and MSD needs to accumulate factors other than the number of MRs to gain a comprehensive competitive advantage.

Conversely, this means that Ono Pharmaceutical can occupy the entire market by maintaining or strengthening its current superiority.

I tried to calculate the trend of market share using the Excel Trend function, and it turns out that by 2027, the outcome of the competition between the two will be completely settled (according to market share theory, the target market share is not 100% but 73.9%).

The expiration of the domestic patent for “Opdivo” is announced to be in March 2031, so for the next four years, Ono Pharmaceutical will be the overwhelmingly dominant player (assuming no new competing products are introduced).

By concentrating resources on facilities/customers classified in the Ab, Bb matrix frames and thoroughly suppressing MSD, it will be possible to reach a resolution even earlier.

The ideal data to use is indication-specific data, not facility/customer order data.

The greatest advantage of analysis using order data is that it allows you to analyze not only your company but also your competitors at the same time.

A strategic plan based on matrix analysis is a method that thoroughly attacks the weaknesses of competitors.

Many pharmaceutical companies have order data, but by combining it with matrix analysis, they should be able to take the initiative against competing companies and achieve victory before being counterattacked.